Background
==========

We aimed to assess the clinical significance of tumour-infiltrating FOXP3+ regulatory T cells (T~R~) in breast cancer patients with long-term follow-up.

Methods
=======

FOXP3+ T~R~were detected by immunohistochemistry with our new FOXP3 monoclonal antibody, 236A/E7. Numbers of FOXP3+ lymphocytes in tissue microarray cores from pure ductal carcinoma *in situ*(DCIS) (*n*= 62), from invasive breast cancer (*n*= 237) or from comparable areas of normal terminal duct lobular breast tissue from patients without cancer (*n*= 10) were determined. A median cutoff value of 15 defined patients with high numbers of T~R~.

Results
=======

T~R~numbers were significantly higher in DCIS and invasive breast carcinomas when compared with normal breast, with invasive tumours having significantly higher numbers than DCIS (*P*= 0.001). High numbers of FOXP3+ T~R~identified patients with DCIS at increased risk of relapse (*P*= 0.04) and patients with invasive tumours having both shorter relapse-free (*P*= 0.004) and overall survival (*P*= 0.007). High T~R~numbers were present in high-grade tumours (*P*\< 0.001), in patients with lymph node involvement (*P*= 0.01) and in estrogen receptor alpha (ER)-negative tumours (*P*= 0.001). Importantly, quantification of FOXP3+ T~R~identified a group at high risk of relapse, within the so-called good prognostic group of ER-positive patients (*P*= 0.005) and these patients have a prognosis as poor as those that lack ER expression. Multivariate analyses, in ER-positive patients, demonstrated that greater T~R~numbers independently conferred a significantly higher hazard ratio than that of tumour grade and nodal status for relapse-free and overall survival, respectively. Unlike conventional clinicopathological factors, high numbers of FOXP3+ T~R~identified patients at risk of late relapse after 5 years disease-free survival.

Conclusion
==========

These findings indicate that quantification of FOXP3+ T~R~in breast tumours is valuable for assessing disease prognosis and progression, and represents a novel marker for identifying late-relapse patients who may benefit from aromatase therapy after 5 years of tamoxifen treatment. Furthermore, tumour vaccination approaches in combination with targeting T~R~cells are just entering clinical trials and our data strongly suggest that such therapy would be beneficial for a significant proportion of breast cancer patients.
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